|
|||||
|
|
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized,phase 3 INO-VATE study |
|
| Authors: | Hagop M. Kantarjian MD Daniel J. DeAngelo MD Matthias Stelljes MD Michaela Liedtke MD Wendy Stock MD Nicola Gökbuget MD Susan M. O’Brien MD Elias Jabbour MD Tao Wang PhD Jane Liang White ScD Barbara Sleight MD Erik Vandendries MD Anjali S. Advani MD |
| Affiliation: | 1. The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Dana-Farber Cancer Institute, Boston, Massachusetts;3. University Hospital Münster, Münster, Germany;4. Stanford Cancer Institute, Stanford, California;5. University of Chicago, Chicago, Illinois;6. Goethe University, Frankfurt, Germany;7. Irvine Medical Center, University of California, Orange, California;8. Pfizer Inc, Groton, Connecticut;9. Pfizer Inc, Cambridge, Massachusetts;10. Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio |
| Abstract: | |
| Keywords: | acute lymphoblastic leukemia adults hematopoietic stem cell transplantation hepatic veno-occlusive disease inotuzumab ozogamicin remission induction |